# Bluegrass Vascular Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bluegrass-vascular-technologies

- Industry: Medical Devices & Equipment
- Headquarters: San Antonio, US
- Website: www.bluegrassvascular.com
- Total disclosed funding: $4.5M
- Latest round: Series A (Jul 30, 2014)
- Investors on record: 1

## About

Bluegrass Vascular Technologies specializes in creating advanced medical devices that improve vascular access procedures, particularly for patients requiring long-term therapies such as hemodialysis and chemotherapy.Founded in 2011 and headquartered in San Antonio, US, Bluegrass Vascular Technologies focuses on innovative medical solutions. Gabriele Niederauer serves as the CEO. The company raised USD 4.5 mn in Series A funding in July 2014, led by Targeted Technology Fund II. Since inception, it has completed 2 deals.Bluegrass Vascular Technologies, Inc. specializes in the development of innovative medical devices aimed at enhancing vascular access procedures for patients requiring long-term therapies. Their core product, the Surfacer® Inside-Out® Access Catheter System, introduces a minimally invasive approach to establish vascular access while mitigating complications associated with traditional methods. This system is particularly beneficial for patients undergoing hemodialysis, chemotherapy, or nutritional therapies, who often depend on reliable vascular access. The company’s "Don't Go Left" strategy focuses on avoiding the use of left-sided veins, thereby improving patient outcomes and preserving future access options. Bluegrass Vascular's products are marketed primarily in the United States and in countries that recognize the CE Mark, targeting healthcare providers, hospitals, and clinics that serve patients with chronic health conditions necessitating reliable vascular access.Bluegrass Vascular operates on a transactional model that focuses on direct sales of its medical devices, specifically the Surfacer® Inside-Out® Access Catheter System, to hospitals and healthcare facilities. The company engages in business-to-business transactions, where healthcare providers purchase these devices to enhance their treatment offerings for patients requiring vascular access. Revenue is generated through direct sales agreements, which are structured to provide healthcare providers with the necessary tools to improve patient care while managing costs associated with vascular complications. The pricing structure for these products reflects the value they deliver in terms of reduced complications and improved patient outcomes. Bluegrass Vascular’s revenue is closely tied to the adoption of its flagship product within the healthcare sector, aligning its financial performance with the needs of patients and providers alike.Bluegrass Vascular Technologies plans to utilize the recent Series A funding of USD 4.5 mn, raised in July 2014, to support the development and launch of new products aimed at enhancing vascular access. The company is focused on expanding its market presence not only in the United States but also in European markets where the CE Mark is recognized, with a goal to achieve significant penetration by 2025. This strategic expansion is designed to enhance the availability of their innovative products to healthcare providers and improve patient outcomes across diverse healthcare settings.

## Funding rounds

- Series A, Jul 30, 2014, $4.5M — Targeted Technology

## Investors

- Targeted Technology (https://capitalatlas.ai/funds/targeted-technology) — Series A